ReviewActa Cardiologica Sinica2020

Appropriate Use of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Atherosclerotic Cardiovascular Disease: Comparison of Recommendations from Different Guidelines or Consensus Around the World.

Jia-Ling Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.